Skip to main navigation
Top Links - Left
BioNTech.com
Newsroom
Investors
Healthcare Professionals
English
Language switcher (Content)
English
German
Top Links - Right
Connect
Main Navigation
BioNTech.com
News
Events & Presentations
Financials
Financials
SEC Filings
Annual Reports
Quarterly Reports
Financial Calendar
Corporate Governance
Corporate Governance
Overview
Transparency
ESG
Stock Info
Stock Info
Stock Quote & Chart
Analyst Coverage
Shareholder Fraud Warning
Share Repurchase Program
Dividend Information
Investor FAQs
Annual General Meeting
Annual General Meeting
Annual General Meeting 2024
Annual General Meeting Archive
Contact Us
Newsroom
Investors
Healthcare Professionals
Breadcrumb
Investors
Search
Search
Filter by content type
(-)
News
(91)
Filter by content year
(-)
2022
(91)
Filter by form group
Filter by category
(-)
Other
(91)
All
(78)
Collaborators
(59)
Clinical
(17)
Events
(14)
Financial
(8)
HR
(2)
Filter by category
Search
News
Pfizer und BioNTech vervollständigen Zulassungsantrag für an Omikron BA.4/BA.5 angepassten bivalenten Impfstoff an die Europäische Arzneimittel-Agentur
News
Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4/BA.5 Adapted Bivalent Vaccine
News
Statement zu von Moderna eingereichtem Patentrechtsstreit
News
Statement on Patent Infringement Lawsuit Filed by Moderna
News
Pfizer und BioNTech erhalten FDA-Notfallzulassung für Auffrischungsimpfung mit an Omikron BA.4/BA.5 angepassten bivalenten COVID-19-Impfstoff für Personen ab 12 Jahren
News
Pfizer and BioNTech Granted FDA Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Ages 12 Years and Older
News
Pfizer und BioNTech erhalten positive CHMP-Empfehlung für Auffrischungsimpfung mit Omikron BA.1-angepasstem bivalenten COVID-19-Impfstoff in der Europäischen Union
News
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.1-Adapted Bivalent COVID-19 Vaccine Booster in European Union
News
BioNTech CEO Ugur Sahin besuchte Israel: Diskussion möglicher Zusammenarbeit bei der Pandemievorsorge und der Entwicklung innovativer Medikamente
News
BioNTech CEO Ugur Sahin Visited Israel to Discuss Cooperation on Pandemic Preparedness and the Development of Innovative Medicines
Pagination
Page 1
Next page
››